ClinicalTrials.gg
CompletedNCT00291759Updated Jan 30, 2013

ABCSG 8 - Adjuvant Treatment in Patients With Hormone Receptor-positive Breast Cancer With Good to Moderate Differentiation.

A Phase 3 interventional study of Tamoxifen and Anastrozole in Breast Cancer, sponsored by AstraZeneca. Completed at 52 sites in Austria. Open to female participants aged Up to 80 Years. Per ClinicalTrials.gov, last updated 2013-01-30.

Sponsored by AstraZeneca · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
3,858
Allocation
Randomized
Ages
Up to 80 Years
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 133 studies testing tamoxifen in Breast Neoplasms — 16 open to participants now, 30 under way, 9 of them phase 3. Tamoxifen · Breast Neoplasms.

Enrollment
12th of 126
3,858 · median 169
Started
1996
with 5 others
Phase 3
57 of 133
4 open now
Registered
44th of 133
by date
Lead sponsor
5 of 133
AstraZeneca

Among the 133 studies testing tamoxifen in Breast Neoplasms, this one is the 12th largest by enrollment of the 126 interventional ones that give a count, is one of 6 that started in 1996, is one of 57 in phase 3, and was the 44th registered.

Breast Neoplasms

14,837 studies on the registry are indexed under Breast Neoplasms; 3,322 are open to participants now.

Browse Breast Neoplasms studies →

Open to participants now

16 of the 133 studies testing tamoxifen in Breast Neoplasms are open now, in 8 countries. Recruiting first, the newest first:

11 more — sign in →

By country, each count listing its studies:

All 16 open studies →

About tamoxifen

Tamoxifen: first FDA approval 1977 (NOLVADEX). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 2,400 Breast Neoplasms studies recruiting now, 1,572 (66%) set no upper age limit and 591 (25%) stop at 75 or younger; 103 take children under 18; 214 take healthy volunteers.

This study: Up to 80 Years · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 133 studies testing tamoxifen in Breast Neoplasms, or all of them as a file.
02

Study summary

The purpose of this study is to assess the difference in event-free survival between postmenopausal women with hormone receptor-positive early breast cancer who switched from tamoxifen to anastrozole and those who continued to receive tamoxifen.

03

Conditions studied

  • Breast Cancer

Browse trials for

04

Who can participate

Ages eligible
Up to 80 Years
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Invasive mammary carcinoma after radical treatment, without prior chemo/hormone/radiation therapy.
  • At least 6 lymph nodes examined.
  • Good or intermediate tumour differentiation.
  • \<6 weeks before start of therapy.
  • Oestrogen or Progesterone positive

Exclusion criteria

Exclusion Criteria:

  • Premenopausal.
  • Preoperative hormonal/antihormonal/radiation/cytoxic chemo. Second malignant tumour/status post second malignant tumour.
  • In-situ/T4 carcinoma.
  • Age >80 years.
  • World Health Organisation performance index >3.
  • Serious accompanying diseases
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
3,858 participants (actual)

Interventions

06

What researchers measure

Primary outcomes

  1. To assess the difference in event free survival and overall survival (subject to stand-alone or combined/meta-analysis) between postmenopausal women with HR +ve early BC who switched from tamoxifen to anastrozole and those who continued on tamoxifen.

Secondary outcomes

  1. To assess the difference in event free survival & overall survival (subject to stand-alone or combined/meta-analysis) plus side effects between postmenopausal women with HR+ve early BC who switched from tam to anastrozole and those who continued on tam.

07

Study locations

52 sites
  • Research Site
    Amstetten, Austria
  • Research Site
    Bad Ischl, Austria
  • Research Site
    Baden, Austria
  • Research Site
    Bregenz, Austria
  • Research Site
    Bruck/Mur, Austria
  • Research Site
    Dornbirn, Austria
  • Research Site
    Eisenstadt, Austria
  • Research Site
    Feldbach, Austria
  • Research Site
    Feldkirch, Austria
  • Research Site
    Freistadt, Austria
  • Research Site
    Fuerstenfeld, Austria
  • Research Site
    Gmuend, Austria
  • Research Sites
    Graz, Austria
  • Research Site
    Guessing, Austria
  • Research Site
    Hainburg, Austria
  • Research Site
    Hartberg, Austria
  • Research Site
    Hollabrunn, Austria
  • Research Site
    Horn, Austria
  • Research Site
    Innsbruck, Austria
  • Research Site
    Judenburg, Austria
  • Research Site
    Kirchdorf, Austria
  • Research Site
    Klagenfurt, Austria
  • Research Sites
    Klosterneuburg, Austria
  • Research Site
    Kufstein, Austria
  • Research Site
    Leoben, Austria
  • Research Sites
    Linz, Austria
  • Research SIte
    Melk, Austria
  • Research Site
    Mistelbach, Austria
  • Research Site
    Moedling, Austria
  • Research Site
    Neunkirchen, Austria
  • Research Site
    Oberpullendorf, Austria
  • Research Site
    Oberwart, Austria
  • Research Site
    Ried im Innkreis, Austria
  • Research Site
    Rohrbach, Austria
  • Research Site
    Rottenmann, Austria
  • Research Site
    Salzburg, Austria
  • Research Site
    Schaerding, Austria
  • Research Site
    Scheibbs, Austria
  • Research Site
    Schladming, Austria
  • Research Site
    Schwarzach/Pongau, Austria
  • Research Site
    Spittal/Drau, Austria
  • Research Site
    St. Poelton, Austria
  • Research Site
    St. Veit/Glan, Austria
  • Research Site
    Steyr, Austria
  • Research Site
    Tulln, Austria
  • Research Sites
    Vienna, Austria
  • Research Site
    Villach, Austria
  • Research Site
    Voecklabruck, Austria
  • Research Site
    Waidhofen/Thaya, Austria
  • Research Site
    Wels, Austria
  • Research Site
    Wolfsberg, Austria
  • Research Site
    Zams, Austria
08

References and documents

Publications

  • Sestak I, Cuzick J, Dowsett M, Lopez-Knowles E, Filipits M, Dubsky P, Cowens JW, Ferree S, Schaper C, Fesl C, Gnant M. Prediction of late distant recurrence after 5 years of endocrine treatment: a combined analysis of patients from the Austrian breast and colorectal cancer study group 8 and arimidex, tamoxifen alone or in combination randomized trials using the PAM50 risk of recurrence score. J Clin Oncol. 2015 Mar 10;33(8):916-22. doi: 10.1200/JCO.2014.55.6894. Epub 2014 Oct 20. PubMed 25332252 ↗
  • Gnant M, Filipits M, Greil R, Stoeger H, Rudas M, Bago-Horvath Z, Mlineritsch B, Kwasny W, Knauer M, Singer C, Jakesz R, Dubsky P, Fitzal F, Bartsch R, Steger G, Balic M, Ressler S, Cowens JW, Storhoff J, Ferree S, Schaper C, Liu S, Fesl C, Nielsen TO; Austrian Breast and Colorectal Cancer Study Group. Predicting distant recurrence in receptor-positive breast cancer patients with limited clinicopathological risk: using the PAM50 Risk of Recurrence score in 1478 postmenopausal patients of the ABCSG-8 trial treated with adjuvant endocrine therapy alone. Ann Oncol. 2014 Feb;25(2):339-45. doi: 10.1093/annonc/mdt494. Epub 2013 Dec 16. PubMed 24347518 ↗
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jan 1996, a primary completion of Jun 2009 and a completion of Jun 2009. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 13, 2006
First posted
Feb 15, 2006
Start
Jan 1996
Primary completionActual
Jun 2009
CompletionActual
Jun 2009
Last update
Jan 30, 2013
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 30, 2013, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT00291759
Lead sponsor
AstraZeneca
Responsible party
Sponsor
First posted
Feb 15, 2006
Start date
Jan 1996
Primary completion
Jun 2009
Completion
Jun 2009
Last update
Jan 30, 2013

Study contacts

Raimund Jakesz, MD
principal investigator · Austrian Breast and Colorectal Cancer Study Group
AstraZeneca Austria Medical Director, MD
study director · AstraZeneca
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2013. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Tamoxifen · Anastrozole

Start the discussion